INS and type 2 diabetes mellitus: In 1997, Mukherjee R. et al. first reported that a synthetic activator of RXR functions as an insulin sensitizer, markedly decreasing serum glucose and insulin levels in mouse models of type 2 diabetes and obesity [102].